These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12228778)

  • 21. What can we expect from prophylactic implantable defibrillators?
    Wilber DJ; Kall JG; Kopp DE
    Am J Cardiol; 1997 Sep; 80(5B):20F-27F. PubMed ID: 9291446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amiodarone: what have we learned from clinical trials?
    Naccarelli GV; Wolbrette DL; Dell'Orfano JT; Patel HM; Luck JC
    Clin Cardiol; 2000 Feb; 23(2):73-82. PubMed ID: 10676597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?
    Stevenson WG; Ridker PM
    JAMA; 1996 Aug; 276(6):481-5. PubMed ID: 8691557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can antiarrhythmic drugs survive survival trials?
    Pratt CM; Waldo AL; Camm AJ
    Am J Cardiol; 1998 Mar; 81(6A):24D-34D. PubMed ID: 9537220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy.
    Droogan C; Patel C; Yan GX; Kowey PR
    Heart Fail Clin; 2011 Apr; 7(2):195-205, viii. PubMed ID: 21439498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why the antiarrhythmics versus implantable defibrillator (AVID) trial sets the wrong precedent.
    Fogoros RN
    Am J Cardiol; 1997 Sep; 80(6):762-5. PubMed ID: 9315584
    [No Abstract]   [Full Text] [Related]  

  • 30. Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy.
    Singh SN; Fletcher RD
    Am J Cardiol; 1999 Nov; 84(9A):103R-108R. PubMed ID: 10568668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting and preventing sudden death from cardiac causes.
    Gilman JK; Jalal S; Naccarelli GV
    Circulation; 1994 Aug; 90(2):1083-92. PubMed ID: 7913885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study.
    Greene HL
    Am Heart J; 1994 Apr; 127(4 Pt 2):1171-8. PubMed ID: 8160597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
    Prystowsky EN
    Rev Cardiovasc Med; 2003; 4 Suppl 2():S47-54. PubMed ID: 12776013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amiodarone and "primary" prevention of sudden death: critical review of a decade of clinical trials.
    Farré J; Romero J; Rubio JM; Ayala R; Castro-Dorticós J
    Am J Cardiol; 1999 Mar; 83(5B):55D-63D. PubMed ID: 10089841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
    Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
    Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs to prevent sudden cardiac death.
    Erath JW; Hohnloser SH
    Int J Cardiol; 2017 Jun; 237():22-24. PubMed ID: 28341373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta-blockers and amiodarone for the primary prevention of sudden cardiac death.
    Frankenberger O; Steinberg JS
    Curr Cardiol Rep; 1999 Nov; 1(4):274-81. PubMed ID: 10980854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.